Proactive Investors - Run By Investors For Investors

Osprey Medical bags $10.3M as sales gain momentum

The company is focused on protecting patients from the harmful effects of X-ray dye.
A person looking at an X-ray
Osprey is accelerating the commercialisation of its systems in the U.S.

Osprey Medical Inc (ASX:OSP) has successfully completed its fully underwritten, non-renounceable entitlement offer to raise circa $10.3 million.

The company has now raised a total of $32.5 million through the entitlement offer and a placement offer, which will be used to support its promising growth trajectory.

Osprey is a U.S. based company focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures.

The company obtained European Regulatory approval, TGA approval, and U.S. FDA clearance for its AVERT™, AVERT Plus and DyeVert™ System after successful clinical trials.

Osprey’s products are designed to reduce the amount of dye injected into patients during standard cardiovascular and peripheral procedures (angiogram and stenting).

It is worth noting that circa 25% of patients undergoing such procedures have pre-existing kidney diseases and are at a high risk of further kidney damage.

DyeVert™ System is a next-generation product that reduces contrast while maintaining image quality in a self-adjusting, easy-to-use design.

The company’s sales activity continues to gain momentum as it accelerates the commercialisation of the DyeVert™ and DyeVert™ Plus Systems in the U.S.

The company’s patent portfolio comprises of 10 issued U.S. patents, 14 issued international patents and 15 pending U.S. patent applications.

View full OSP profile View Profile

Osprey Medical Ltd Timeline

Related Articles

scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
scientist with vial
September 25 2018
The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
surgeons working
September 03 2018
Chief executive Steve Couldwell also told investors the regenerative medicines specialist had identified a number of potential new commercial opportunities it was “actively pursuing”

© Proactive Investors 2019

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use